What is Netupitant Palonosetron FDC Market?
The Netupitant Palonosetron FDC is an oral therapy that targets two critical pathways associated with acute and delayed CINV by blockage of P/NK1 receptors. It is the first approved fixed-dose combination drug for the prevention of chemotherapy-induced nausea and vomiting. Chemotherapy, not only kills the cancer cells but also attacks healthy cells that lead to side effects such as fatigue, hair loss, nausea, and vomiting. Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the most serious side effects that is taken into account.
The market study is being classified by Type (Patient Pool), by Application (Chemotherapy and Others) and major geographies with country level break-up.
Helsinn Healthcare S.A (Switzerland), Heron Therapeutics Inc. (United States) and Acacia Pharma (United Kingdom) are some of the key players profiled in the study.
Analyst at AMA have segmented the market study of Global Netupitant Palonosetron FDC market by Type, Application and Region.
On the basis of geography, the market of Netupitant Palonosetron FDC has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Growing Number of Patients Undergoing Chemotherapy
- Introduction of Novel Delivery Method of FDC to Improve Patient Compliance
- Replacement of Monotherapy by Combination Therapy
- Adverse Effect Caused by Netupitant Palonosetron FDC
- High Cost Associated with Netupitant Palonosetron FDC
- Efficacy of Palonosetron is High than Other Serotonin Inhibitors
- Improvements in the Control of CINV by FDC Drug
Netupitant – Palonosetron FDC is approved by U.S Food and Drug Administration for the prevention of acute nausea and vomiting during the cancer treatment process. Palonosetron was approved by FDA in 2008.
Key Target AudienceNetupitant Palonosetron FDC Vendors, Pharmaceutical & Healthcare Organizations, Research Institutes and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase